flowchart LR
subgraph Biomarker_Types
A[Biomarkers] --> B[CSF<br>Cerebrospinal Fluid] -->
A --> C[Blood<br>Plasma/Serum] -->
A --> D[Imaging<br>PET/MRI] -->
A --> E[Genetic<br>DNA/RNA]
end
B --> B1[Aβ40, Aβ42] -->
B --> B2[t-tau, p-tau] -->
B --> B3[NfL, GFAP] -->
C --> C1[p-tau217, p-thi181] -->
C --> C2[NfL, GFAP] -->
C --> C3[Aβ, α-syn] -->
D --> D1[Amyloid PET)
D --> D2[Tau PET)
D --> D3[Structural MRI] -->
E --> E1[APOE genotyping)
E --> E2[Mutations] -->
E --> E3[Gene expression]
style A fill:#E6F3FF
style B fill:#FFE6E6
style C fill:#E6FFE6
style D fill:#FFF3E6
style E fill:#F3E6FF
Biomarkers In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Biomarkers are measurable indicators of biological processes, pathological conditions, or pharmacological responses to therapeutic interventions. In [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases, biomarkers serve critical roles in early diagnosis, disease staging, prognosis, patient stratification for clinical trials, and monitoring treatment response. The development of reliable biomarkers has accelerated dramatically in recent years, with blood-based assays now approaching the diagnostic accuracy of cerebrospinal fluid (CSF) and neuroimaging measures for several conditions (Jack et al., 2024; Hansson, 2024) [1].
While [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- has the most developed biomarker landscape (see [Biomarkers of Alzheimer's Disease] for detailed AD-specific coverage), significant progress has been made in biomarker development for [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, and other neurodegenerative conditions [2].
- Cerebrospinal fluid (CSF): Direct sampling of the fluid surrounding the brain; high sensitivity but requires lumbar puncture
- Blood (plasma/serum): Minimally invasive; rapidly advancing in diagnostic accuracy
- Imaging: Structural (MRI), functional (fMRI), and molecular (PET) modalities provide spatial information
- Digital: Wearable sensors, smartphone apps, and digital cognitive tests
- Other: Retinal imaging, olfactory testing, skin biopsies, saliva
The 2024 revised [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- criteria established a framework applicable across neurodegenerative diseases (Jack et al., 2024):
- Core disease biomarkers: Directly reflect defining pathological features (e.g., [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, tau]] for AD; [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- for PD)
- Biomarkers of neurodegeneration: Reflect neuronal injury/death regardless of underlying cause (e.g., [neurofilament light (NfL))
- Biomarkers of neuroinflammation: Reflect glial activation and inflammatory processes (e.g., [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX--
- Biomarkers of synaptic dysfunction: Reflect synaptic loss and [synaptic dysfunction[/mechanisms/[synaptic-dysfunction[/mechanisms/[synaptic-dysfunction[/mechanisms/[synaptic-dysfunction--TEMP--/mechanisms)--FIX--
[Neurofilament light chain ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- is a cytoskeletal protein of [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- that is released into the CSF and blood upon axonal damage. It is the most established cross-disease biomarker of neurodegeneration:
- Elevated in: [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- (markedly), [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, [AD], [PD], [HD], [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--, [PSP[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--, [CJD[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob--TEMP--/diseases)--FIX--, [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--, traumatic brain injury
- Clinical utility: Prognostic marker correlating with disease progression rate, particularly useful in ALS where baseline [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- predicts survival; discriminates between neurodegenerative conditions and psychiatric mimics
- Limitations: Not disease-specific; elevated in many neurological conditions; high plasma [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- is more associated with non-AD neurodegeneration and executive dysfunction than typical AD cognitive profiles (Pan et al., 2025)
- Assay platforms: Simoa (Single Molecule Array), Lumipulse, Ella; FDA-cleared assays now available for clinical use
[GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- is an intermediate filament protein expressed primarily by [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--. Plasma [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- has emerged as a biomarker of astrocytic activation and [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--:
- In AD: Plasma [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- correlates with [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- pathology and may reflect the astrocytic response to amyloid deposition; elevated [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- levels modify the relationship between amyloid and tau]] progression (Pan et al., 2025)
- In other diseases: Elevated in [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--, [neuromyelitis optica[/diseases/[neuromyelitis-optica[/diseases/[neuromyelitis-optica[/diseases/[neuromyelitis-optica--TEMP--/diseases)--FIX--, traumatic brain injury, and other conditions with astrogliosis
- Prognostic value: Elevated baseline [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- predicts future cognitive decline and dementia incidence (Hansson, 2024)
Multiple phosphorylated tau species serve as biomarkers, with differing diagnostic profiles:
- [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--: Highest diagnostic accuracy for AD; strongly predicts hippocampal atrophy and cognitive decline in [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---positive individuals; plasma %[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- performance is equivalent or superior to FDA-approved CSF tests (Zhong et al., 2025)
- p-tau181: Widely validated; CSF p-tau181 is part of the core AD biomarker panel; distinguishes AD from non-AD dementias
- p-tau231: Earliest p-tau change in AD; rises before amyloid PET positivity; may detect the earliest stages of AD pathology
- p-tau205: Correlates with tau PET signal and may reflect tangle formation more directly than other p-tau species
The ratio of [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- 42 to [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- 40 in CSF and plasma reflects cerebral amyloid deposition:
- CSF Aβ42/Aβ40: Core 1 AD biomarker; decreases as amyloid deposits in the brain sequester Aβ42
- Plasma Aβ42/Aβ40: Can detect early-stage AD and correlates with amyloid PET (Leuzy et al., 2025)
- Clinical implementation: Mass spectrometry (IP-MS) and immunoassay platforms (Lumipulse, Simoa) now available for clinical use
A breakthrough for [synucleinopathies[/mechanisms/[synucleinopathies[/mechanisms/[synucleinopathies[/mechanisms/[synucleinopathies--TEMP--/mechanisms)--FIX--, seed amplification assays detect misfolded [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregates in CSF:
- Diagnostic accuracy: >90% sensitivity and specificity for [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- and [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- vs. healthy controls
- Disease differentiation: Can distinguish PD/DLB from [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX-- based on different aggregation kinetics
- Biological definition: Enables biological (rather than purely clinical) diagnosis of synucleinopathies, analogous to amyloid/tau biomarkers in AD
- Limitations: Currently requires CSF; blood-based SAA under development
| Disease |
Key Biomarkers |
Matrix |
| [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- |
[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--, Aβ42/Aβ40, [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- |
CSF, plasma |
| [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- |
αSyn-SAA, [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- |
CSF, plasma |
| [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- |
[NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- (markedly elevated), pNfH |
CSF, plasma |
| [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- |
[NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX--, [GRN[/genes/[grn[/genes/[grn[/genes/[grn--TEMP--/genes)--FIX-- (for GRN mutations) |
CSF, plasma |
| [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- |
Mutant [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- (mHTT), [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- |
CSF |
| [CJD[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob--TEMP--/diseases)--FIX-- |
RT-QuIC (prion SAA), 14-3-3, [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, total tau |
CSF |
| [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX-- |
αSyn-SAA, [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- |
CSF |
Magnetic resonance imaging provides measures of brain atrophy that serve as biomarkers across neurodegenerative diseases:
- Volumetric MRI: Hippocampal volume loss in [AD]; [caudate] atrophy in [HD]; frontal/temporal atrophy in [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--
- Cortical thickness mapping: Reveals disease-specific atrophy patterns related to [selective neuronal vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability--TEMP--/mechanisms)--FIX--
- White matter integrity (DTI): Detects axonal degeneration and demyelination
- Susceptibility-weighted imaging (SWI): Detects iron deposition relevant to [NBIA[/diseases/[nbia[/diseases/[nbia[/diseases/[nbia--TEMP--/diseases)--FIX-- and other conditions
[amyloid PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX-- imaging using tracers such as florbetapir (^18F), florbetaben, and flutemetamol directly visualizes [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- plaque deposition in the living brain:
- Detects brain amyloid earlier than CSF biomarkers in some studies (Lowe et al., 2024)
- Essential for confirming amyloid status in clinical trials of [anti-amyloid therapeutics[/mechanisms/[anti-amyloid-therapeutics[/mechanisms/[anti-amyloid-therapeutics[/mechanisms/[anti-amyloid-therapeutics--TEMP--/mechanisms)--FIX-- such as [lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab--TEMP--/treatments)--FIX-- and [donanemab[/treatments/[donanemab[/treatments/[donanemab[/treatments/[donanemab--TEMP--/treatments)--FIX--
- Used to monitor treatment response (amyloid clearance) and detect [ARIA] complications
[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- PET tracers (^18F-flortaucipir, ^18F-MK6240, ^18F-PI2620) visualize tau aggregates and provide information on Braak staging in vivo:
- Correlates with cognitive status more strongly than amyloid PET
- Discriminates AD from non-AD dementias with high accuracy
- Detects tau pathology] patterns corresponding to different AD clinical variants (e.g., [posterior cortical atrophy[/diseases/[posterior-cortical-atrophy[/diseases/[posterior-cortical-atrophy[/diseases/[posterior-cortical-atrophy--TEMP--/diseases)--FIX--, [primary progressive aphasia)
Dopamine transporter (DAT) imaging with DaTscan reflects [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX--rgic terminal integrity in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--:
- Core diagnostic biomarker for [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- and [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--
- Distinguishes neurodegenerative parkinsonism from essential tremor and drug-induced parkinsonism
- Reduced DAT binding correlates with motor symptom severity
^18F-fluorodeoxyglucose PET reveals patterns of cerebral hypometabolism characteristic of each disease:
- AD: Temporoparietal and posterior cingulate hypometabolism
- FTD: Frontal and/or anterior temporal hypometabolism
- DLB: Occipital hypometabolism (distinguishing feature from AD)
- PSP: Midbrain and frontal hypometabolism
Digital biomarkers represent an emerging frontier leveraging consumer technology and wearable devices for continuous, real-world assessment of neurological function (Dorsey et al., 2017):
- Gait analysis: Wearable accelerometers detect subtle gait changes in prodromal [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- and fall risk in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--; the UK Biobank accelerometry data has been used to identify pre-diagnostic motor signatures (Del Din et al., 2019)
- Speech analysis: AI-powered analysis of speech patterns (pause frequency, articulation rate, semantic content) for early detection of AD, PD, and [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--; FDA breakthrough device designations granted for several platforms
- Digital cognitive testing: Smartphone-based cognitive assessments (e.g., Linus Health, Cogstate) enabling frequent, remote monitoring with reduced practice effects compared to traditional testing
- Sleep monitoring: Wearable sleep trackers detecting REM sleep behavior disorder (a prodromal marker of alpha-synucleinopathies), sleep fragmentation, and circadian disruption
- Tremor quantification: Smartphone gyroscope and accelerometer data provide objective tremor measurement in PD clinical trials, enabling continuous monitoring outside clinic visits (Zhan et al., 2018)
- Typing patterns: Keystroke dynamics as markers of motor and cognitive function; altered typing speed and error patterns can detect early cognitive decline
The development of ultra-sensitive assay platforms has transformed blood-based biomarker research:
- Single Molecule Array (Simoa): Digital ELISA technology achieving sub-femtomolar sensitivity
- Meso Scale Discovery (MSD): Electrochemiluminescence platform widely used in clinical trials
- Immunoprecipitation–Mass Spectrometry (IP-MS): Highest accuracy for Aβ42/Aβ40 ratio measurement
- Lumipulse: Automated chemiluminescence platform with FDA-cleared assays
- Blood-based biomarkers can predict AD dementia up to 16 years before onset (Hansson, 2024)
- Plasma %[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- is clinically equivalent to FDA-approved CSF tests for amyloid classification (Zhong et al., 2025)
- Elevated baseline p-tau181, [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--, [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, and [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- are associated with significantly increased hazard for all-cause and AD dementia with non-linear dose–response relationships (Hansson, 2024)
- Multi-biomarker panels combining [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- + Aβ42/Aβ40 + [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- + [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- outperform individual markers
¶ Challenges and Future Directions
¶ Standardization
Biomarker standardization is critical for clinical adoption and cross-study comparison (Hansson et al., 2018):
- Assay harmonization: The Global Biomarker Standardization Consortium and the Alzheimer's Association QC Program work to harmonize CSF and blood biomarker assays across platforms (Lumipulse, Elecsys, Simoa); certified reference materials for Abeta42 have been developed
- Pre-analytical variability: Standardized protocols for sample collection (tube type, centrifugation speed, processing time), storage temperature (-80°C), and freeze-thaw cycles are essential; polypropylene tubes required for CSF [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- to prevent adsorption
- Reference materials and quality control: IFCC-certified reference materials for CSF Abeta42 enable traceability across assay platforms; external quality control programs (Alzheimer's Association QC Scheme) provide inter-laboratory performance monitoring
- Cross-platform validation: Head-to-head comparison studies between immunoassay platforms and mass spectrometry reference methods to establish conversion algorithms and universal cutoffs
- Most current biomarkers ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, GFAP) are not disease-specific
- Need for biomarkers that distinguish between overlapping pathologies (e.g., AD + LBD + vascular disease)
- Development of disease-specific seed amplification assays for multiple proteinopathies
Addressing health equity in biomarker research and clinical implementation is essential for equitable neurological care (Babulal et al., 2019):
- Population-specific thresholds: Biomarker cutoff values validated primarily in white European populations may not generalize; for example, [plasma[/diagnostics/[plasma-biomarkers[/diagnostics/[plasma-biomarkers[/diagnostics/[plasma-biomarkers--TEMP--/diagnostics)--FIX-- [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- and [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- levels differ by race/ethnicity, and Abeta42/40 ratios may vary across populations. Validation cohorts must include diverse participants
- Racial/ethnic differences: Black Americans have lower CSF Abeta42 levels than white Americans at the same amyloid PET status, potentially leading to misclassification with race-blind cutoffs (Schindler et al., 2022)
- Access disparities: Advanced biomarker testing (PET imaging, CSF analysis, plasma assays) remains concentrated in academic medical centers in high-income countries; expanding access to blood-based biomarkers is critical for global equity
- Representation in research: Historically, biomarker studies have enrolled predominantly white participants; ongoing efforts (ADNI-4, HABS-HD) explicitly recruit diverse cohorts to address this gap
- Extracellular vesicle biomarkers: Brain-derived [exosomes[/entities/[exosomes[/entities/[exosomes[/entities/[exosomes--TEMP--/entities)--FIX-- in blood may carry disease-specific cargo
- MicroRNA panels: Circulating miRNAs as disease indicators
- Retinal biomarkers: OCT and retinal amyloid imaging as non-invasive windows to brain pathology
- Multi-omics integration: Combining proteomics, metabolomics, and genomics for precision medicine approaches
- [All Mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
The study of Biomarkers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent studies on [biomarkers] strengthen blood-based risk stratification and longitudinal disease-timing models for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
- [Jack, C.R., et al. (2024]. Revised criteria for diagnosis and staging of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: Alzheimer's Association Workgroup. Alzheimer's & Dementia, 20(8), 5143-5169. [PubMed)(https://pubmed.ncbi.nlm.nih.gov/38382006/)
- [Hansson, O. (2024]. Highly accurate blood test for Alzheimer's Disease is similar or superior to clinical cerebrospinal fluid tests. Nature Medicine, 30, 2991-2998. Nature)
- [Pan, F., et al. (2025]. Plasma P-tau217, [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX--, and [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- as biomarkers for Alzheimer's Disease: role in disease stratification, pathological progression, and cognitive decline. Alzheimer's & Dementia, e70987. [Wiley)(https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70987)
- [Zhong, Y., et al. (2025]. Plasma [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- and [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--/Aβ1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer's Disease. Alzheimer's & Dementia, e14536. [Wiley)(https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14536)
- [Leuzy, A., et al. (2025]. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's Disease. Alzheimer's & Dementia, e14528. Wiley)
- Wiley)
- [Abukuri, F.K. (2024]. Novel biomarkers for Alzheimer's Disease: plasma neurofilament light and cerebrospinal fluid. International Journal of Alzheimer's Disease, 6668159. Wiley)
- [Ashton, N.J., et al. (2023]. Plasma biomarkers of Alzheimer's Disease: a review of available assays, recent developments, and implications for clinical practice. Molecular Neurodegeneration, 18, 27. PMC)
- [Batzu, L., et al. (2024]. Plasma [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX--, amyloid, and p-tau species as prognostic biomarkers in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. Journal of Neurology, 271, 7537-7546. [Springer)(https://link.springer.com/article/10.1007/s00415-024-12669-7)
- [Benkert, P., et al. (2025]. The role of neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD. Journal of Neurology, Neurosurgery & Psychiatry, 96, 31-39. PMC)
- [Gaetani, L., et al. (2019]. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery & Psychiatry, 90(8), 870-881. PubMed)
- [Mattsson-Carlgren, N., et al. (2023]. Soluble [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 15(7), e16889. [PubMed)(https://pubmed.ncbi.nlm.nih.gov/37191220/)
- [Mielke et al., Predicting onset of symptomatic Alzheimer's Disease with plasma p-tau217 clocks (2026)(https://pubmed.ncbi.nlm.nih.gov/41714746/)
- [Doecke et al., Diagnostic and prognostic utility of serum beta-synuclein in Alzheimer's Disease: a longitudinal cohort study (2026)(https://pubmed.ncbi.nlm.nih.gov/41763014/)
- Morrow et al., Physical activity across the life course and neural biomarkers (2026)
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
33% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 42%